Velocity is a leader in high-volume vaccine trials and research programs that require access to hard-to-reach patients
Most the world’s leading Sponsors and CROs have made Velocity a strategic partner for their infectious disease research programs. Velocity provides a broad global footprint to support rapid enrollment, even for studies involving sensitive cohorts (e.g., seniors, children, pregnant women, at-risk populations).
Several of Velocity’s principal investigators are also sought after by Sponsors and CROs to guide vaccine-related protocol development. These investigators have had research published in prestigious industry journals, including the New England Journal of Medicine and Vaccine.
Therapeutic expertise
- Anthrax
- Avian Influenza
- C. difficile (C-diff)
- Celiac Disease
- Chikungunya
- Cytomegalovirus (CMV)
- Dengue fever
- Diphtheria
- Ebola
- Encephalitis
- HCMV
- Hepatitis B
- Herpes
- Human metapneumovirus (hMPV)
- Human papillomavirus (HPV)
- Influenza – H1N1, H5N1, H7N1, and H7N9
- Lyme disease
- Meningococcal
- mRNA vaccines
- Norovirus
- Parainfluenza
- Pediatric influenza
- Pediatric meningitis
- Pertussis
- Plague
- Pneumococcal
- Rabies
- Respiratory syncytial virus (RSV), including maternal and pediatric
- SARS-CoV-2 (COVID-19)
- Smallpox
- Tetanus
- Type 3 (PIV3)/RSV combo
- West Nile virus
- Zika virus
- Zoster
The proven site network for novel vaccine research programs
Across any indication, including anti-infectives and immunologics, Velocity is prepared to support your research program for a novel vaccine, diagnostic, or combination product.
In-house monitoring, quality assurance, and audit support
PBMC processing capabilities and central laboratory support
Government-funded, Phase 1, and first-in-human trial experience
2020 Vaccine Industry Excellence (ViE) award winner for Best Clinical Trial Site, Best Clinical Trial Network